Skip to main content
The Journal of Clinical Hypertension logoLink to The Journal of Clinical Hypertension
. 2026 Nov 7;28(11):e70381. doi: 10.1111/jch.70381

Guideline Implementation Gap in Preeclampsia Prevention: Adherence to Low‐Dose Aspirin Use in Routine Obstetric Practice

Nazan Usal Tarhan 1,✉, Nur Durcanoğlu 1, Sevdenur Banu Yiğit 1, Mina Erbıyık 1, Habibe Ayvacı Taşan 1
PMCID: PMC13744444  PMID: 42998900

ABSTRACT

Evidence‐based guidelines recommend the use of low‐dose aspirin (LDA) to prevent preeclampsia. Gaps between recommended and actual care may limit the impact of proven preventive interventions. This study aimed to assess obstetricians’ adherence to LDA prescription for preeclampsia prevention in accordance with the national guideline. This retrospective cohort study included 1150 women who delivered between November 2023 and December 2024. Eligibility for LDA use was determined according to guideline‐defined risk criteria. Adherence was defined as prescribing LDA between 11 and 16 weeks of gestation. The rate of LDA recommendation was assessed and factors associated with LDA prescription were analyzed. 210 women (18.3%) met the criteria for LDA recommendation. However, LDA was prescribed to 97 (46.2%) of these women, indicating that more than half of the candidates missed the opportunity for prophylaxis. Among the 969 women who did not use LDA during pregnancy, 113 (11.7%) actually met the guideline criteria and should have received LDA. In this untreated group, the incidence of preeclampsia was approximately fourfold higher compared with women without an LDA indication (26.5% vs. 8.2%; OR 4.06, 95% CI 2.50–6.58, p < 0.001). Follow‐up at a tertiary healthcare center at or before 16 weeks of gestation was associated with significantly higher rates of appropriate LDA prescription (p < 0.001). Adherence to national guideline for the prevention of preeclampsia remains suboptimal in Türkiye. This implementation gap represents missed opportunities for the prevention of preeclampsia and underscores the need for targeted educational initiatives and system‐level interventions.

Keywords: aspirin, guideline, medical prescription, preeclampsia, pregnancy

1. Introduction

Preeclampsia is hypertension accompanied by new‐onset proteinuria or end‐organ dysfunction after 20 weeks of pregnancy. Preeclampsia and eclampsia are the second most common cause of maternal mortality worldwide [1]. They affect 2–8% of pregnancies globally and are responsible for 46 000 maternal and 500 000 foetal or neonatal deaths annually. Although reducing maternal mortality to below 70 per 100 000 by 2030 is one of the Sustainable Development Goals, current data suggest this target is unlikely to be achieved [2].

Research on the pathophysiology of preeclampsia shifted toward placental development after Browne and Veall showed in 1953 that uteroplacental blood flow was reduced in preeclamptic women. It is now established that preeclampsia is a placental bed disorder [3]. Uteroplacental development is achieved through physiological transformation of uterine spiral arteries, where vascular endothelium is gradually invaded by trophoblasts. In preeclampsia, this transformation is inadequate. Primary, secondary, and tertiary preventive measures for preeclampsia have been described. Primary prevention measures are pregnancy prevention and planning in high‐risk populations and lifestyle changes such as blood pressure, body weight and blood glucose control. The current evidence‐based method for secondary prevention is to use LDA throughout the period of secondary trophoblast invasion [4]. Various health organizations have recommended screening models for the prediction of preeclampsia. These screening methods are structured according to the severity and the number of identified risk factors. These guidelines recommend the use of LDA at 11–16 weeks of gestation in pregnant women with one severe and/or at least two moderate risk factors [5, 6]. The maternal mortality rate in Türkiye decreased from 16.7% to 13.6% between 2010 and 2018 [7]. Hypertensive diseases are the second leading cause of direct maternal mortality. They account for 15.5% (n = 126) of all maternal mortality [8]. Republic of Türkiye Ministry of Health ‘Prenatal Care Management Guideline’ (Türkiye Guideline) reported major and minor risk factors for the prediction of preeclampsia and LDA recommendation in 2018 [9]. The criteria used to define moderate‐ and high‐risk factors for preeclampsia are essentially identical in the Turkish and NICE guidelines [5].

Evidence‐based clinical guidelines play a role in improving the quality of healthcare, and adherence to these guidelines is considered a measure of process quality. However, the existence of guidelines does not guarantee that these recommendations will be consistently implemented in clinical practice. This situation is described as the evidence‐to‐practice gap. Evaluating adherence to guidelines can contribute to identifying gaps in practice and developing targeted quality improvement strategies in maternal health [10].

After the release of the Türkiye Guideline in 2018, observations from routine clinical practice at our center indicated potential gaps in the prescription of LDA among pregnant women who met the risk criteria. In response to this observation, this study was designed to examine the evidence‐to‐practice gap in the recommendation of LDA for the prevention of preeclampsia. To our knowledge, this is the first study conducted in Türkiye to evaluate adherence to national guideline recommendations on LDA use in pregnancy. The findings of this study may inform clinical decision‐making and quality improvement efforts related to LDA prescription, with the potential to enhance the quality of maternal and foetal healthcare services.

2. Methods

2.1. Study Design and Setting

This is a retrospective cohort study. It was conducted at Zeynep Kamil Women and Children's Diseases Training and Research Hospital, İstanbul, Türkiye in postpartum maternity clinic between November 2023 and December 2024. Ethical permission was obtained from the Zeynep Kamil Women and Children's Diseases Training and Research Hospital Clinical Research Ethics Committee (Approval date/number: 20.09.2023/137). The study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all eligible participants.

Study size was calculated with the Open‐Epi program. Based on United States Preventive Services Task Force defined risk criteria indicating that approximately 8% of pregnant women carry an absolute risk for preeclampsia, LDA was assumed to be indicated for 8% of the study population [11]. Assuming a 50% lower actual recommendation rate (4%), a minimum sample size of 1,100 women was required to achieve 95% confidence and 80% power.

2.2. Study Population and Data Source

The researchers recruited patients by visiting the postpartum clinic once a week, in line with their study schedule. Participant recruitment was conducted during the postpartum period; however, all data related to antenatal care and low‐dose aspirin (LDA) use were collected retrospectively. Women aged 18–50 who had given birth after 20 weeks of gestation were included in the study. Patients who refused to participate, had language difficulties, had a psychiatric illness, were taking LDA for reasons other than preeclampsia prevention, or discontinued LDA use before 28 weeks of gestation were excluded.

Patients’ age was verified from ID. Prenatal height and weight were based on measurements taken by the midwife at the time of admission. Weight during the first trimester of pregnancy was verified by electronic records. The obstetric history was obtained from patient's files. Socioeconomic status was classified based on the patient's self‐reported occupation and education level information [12].

Antenatal follow‐up throughout the first 16 weeks of gestation was categorized according to the type of healthcare center. This information was obtained from the national electronic medical records. Smoking during pregnancy was recorded based on patient self‐report. Information about first trimester genetic screening test and pregnancy complications (foetal growth restriction, intrauterine foetal loss, hypertension, preeclampsia, and abruption) were obtained from electronic and printed records. Women were evaluated in terms of LDA indication according to the Republic of Türkiye Ministry of Health ‘Prenatal Care and Management Guideline’ criteria. This guideline identifies several major risk factors, including hypertensive disease in prior pregnancies, chronic renal disease, autoimmune diseases (Systemic lupus erythematosus or antiphospholipid syndrome), diabetes mellitus and chronic hypertension. Minor risk factors are first pregnancy, age ≥40, pregnancy interval >10 years, body mass index (BMI) ≥35 kg/m2, family history of preeclampsia, and multiple pregnancies. If there is at least one major risk factor and at least two minor risk factors, and no contraindication, 80 mg Aspirin is recommended to be initiated after 12th gestational weeks and continued until 35th gestational weeks [9]. Prescriptions recorded in the electronic prescribing system within the first 16 weeks of pregnancy were retrospectively reviewed.

Study variables were collected prospectively through patient interviews, measurements obtained at hospital admission for delivery, and information recorded in the medical records. During data collection, any missing information identified in the medical records was completed by directly questioning the patient or by performing the required measurement whenever applicable. The LDA status was verified using the national electronic prescription system. Cases for which LDA prescription status could not be verified were excluded before analysis. Consequently, no missing data were present in the final analytical dataset.

2.3. Outcome Measures and Definitions

The primary outcome measure was the evaluation of LDA prescription in accordance with the Türkiye Guideline criteria. For the purpose of this study, LDA prescription adherence was defined by the presence of a recorded prescription between 11 and 16 gestational weeks. Adherence to this timing criterion was used as a process‐based quality indicator of compliance with guideline recommendations. Women without documentation of LDA prescription within this period were classified as not having received guideline‐adherent LDA prophylaxis. Preeclampsia was defined as new‐onset hypertension after 20 weeks of gestation and associated proteinuria or end‐organ damage [13].

The total number of risk factors present in each case was defined as the ‘’number of risk factors. The risk value for each woman was calculated by assigning a score of 1 to each minor risk factor and 2 to each major risk factor, based on guideline‐defined risk categories, and summing these values to reflect the cumulative number of risk factors present in each case. Although this is not a weighted risk score, it provides an overall measure of the risk burden for each individual.

2.4. Statistical Analysis

Statistical analysis was carried out with the statistical package program. Descriptive statistics were presented as mean ± standard deviation, median, frequency, and percentage. Kolmogorov‐Smirnov test was used to determine normality of the data distribution. Mann‐Whitney U test was used to compare non‐normally distributed numerical data. Chi‐square tests were used to compare categorical variables. A p value of <0.05 was considered statistically significant. A multivariable logistic regression analysis was performed using the enter method to identify independent predictors of preeclampsia. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.

3. Results

A total of 5771 women delivered between November 2023 and December 2024. Of these, 1200 were invited to participate in the study. Fifty women did not match the inclusion criteria. The study was completed with 1150 women (Figure 1).

FIGURE 1.

FIGURE 1

Flow chart of the study. Number of births between 01.11.2023 and 31.12.2024 (n = 5771). The researchers visited the postpartum clinic once a week for patient recruitment.

3.1. Demographic and Clinical Characteristics of the Study Population

Demographic variables, preeclampsia‐related risk factors, antenatal follow‐up characteristics and complications were studied in patients who were prescribed and were not prescribed LDA in the current pregnancy. Of the cases, 15.7% (n = 181) were prescribed LDA in the current pregnancy, 13.5% (n = 155) developed preeclampsia, and 0.5% (n = 6) developed eclampsia. A total of 210 cases (18.3%) met the criteria for LDA recommendation according to the Türkiye Guideline (Table 1).

TABLE 1.

Demographic and clinical characteristics of the study population.

Total (N = 1150) LDA‐ not prescribed in the current pregnancy (N = 969) LDA‐ prescribed in the current pregnancy (N = 181) p
n % n % n %
Demographic characteristics and risk factors
Age ≥40 years 53 4.6 35 3.6 18 9.9 <0.001
1st trimester BMI≥ 35 kg/m2 77 6.7 53 5.5 24 13.3 <0.001
African‐American race 2 0.2 1 0.1 1 0.6 NA
Socioeconomic status
AB 220 19.1 176 18.2 44 24.3 0.103
C1 257 22.3 213 22.0 44 24.3
C2 484 42.1 413 42.6 71 39.2
DE 189 16.4 167 17.2 22 12.2
Smoking 186 16.2 152 15.7 34 18.8 0.299
Chronic hypertensive disease 31 2.7 10 1.0 21 11.6 <0.001
Type 1 DM 5 0.4 1 0.1 4 2.2 0.003
Type 2 DM 27 2.3 14 1.4 13 7.2 <0.001
SLE 1 0.1 0 0.0 1 0.6 NA
APS 3 0.3 0 0.0 3 1.7 NA
Chronic renal disease 6 0.5 5 0.5 1 0.6 NA
Family history of preeclampsia 69 6 55 5.7 14 7.7 0.284
Last birth >10 years 71 6.2 58 6 13 7.2 0.377
History of recurrent pregnancy loss 58 5 31 3.2 27 14.9 <0.001
Birth weight <2500 g in previous birth and/or history of preterm birth 116 17.3 80 14.1 36 35.0 <0.001
History of preeclampsia (n:670) a 65 9.7 28 4.9 37 35.9 <0.001
History of abruptio placenta (n:670) a 14 2.1 10 1.8 4 3.9 0.249
History of intrauterine foetal loss (n:670) a 24 3.6 11 1.9 13 12.6 <0.001
Primiparity 480 41.7 402 41.5 78 43.1 0.687
Pregnancy with ART 41 3.5 16 1.6 25 13.8 <0.001
Multiple pregnancy 43 3.7 26 2.7 17 9.4 <0.001
Current pregnancy characteristics and complications
Follow up at tertiary healthcare center <16 weeks of gestation 568 49.4 452 46.6 116 64.1 <0.001
Cases with 1st trimester genetic screening test 463 40.3 365 37.7 98 54.1 <0.001
LMWH use in current pregnancy 82 7.1 39 4 43 23.8 <0.001
Intrauterine fetal loss in current pregnancy 7 0.6 6 0.6 1 0.6 1.000
FGR in current pregnancy 153 13.3 115 11.9 38 21.0 0.001
Preeclampsia in current pregnancy 155 13.5 100 10.3 55 30.4 0.001
Eclampsia in current pregnancy 6 0.5 2 0.2 4 2.2 0.007
Ablatio placenta in current pregnancy 17 1.5 11 1.1 6 3.3 0.038
Route of delivery (CS) 778 67.7 636 65.6 142 78.5 0.001
Who met criteria for LDA in accordance with Türkiye Guideline 210 18.3 113 11.7 97 53.6 <0.001
Median IQR Median IQR Median IQR
Gestational week at delivery 38 37‐39 38 37‐39 37 35‐38,5 <0.001
Newborn weight (g) 3100 2660‐3500 3150 2740‐3500 2800 2330‐3365 <0.001

Note: APS, Antiphospolipid syndrome; ART, Assisted reproductive technology; BMI, Body mass index; CS, Caesarean section; DM, Diabetes mellitus; FGR, Foetal growth restriction; IQR, Inter quartile range; LDA, Low‐dose aspirin; LMWH, Low‐molecular‐weight heparin; NA, Not applicable; SLE, Systemic lupus erythematosus. Socioeconomic status: Classified as ‘A’ being the highest and ‘E’ being the lowest.

a

Nulliparas were excluded.

3.2. LDA Prescription Based on Eligibility Criteria

The LDA was prescribed in 8.9% (n = 84) of women who did not have an indication for LDA (n = 940), compared with 46.2% (n = 97) of those who met the criteria for LDA (n = 210) (Table 2).

TABLE 2.

Low‐dose aspirin prescription in women who did not meet vs met the criteria.

Not meeting criteria for LDA Meeting criteria for LDA Total
n % n % n % p
LDA‐ not prescribed in the current pregnancy 856 91.1 113 53.8 969 84.3 <0.001
LDA‐ prescribed in the current pregnancy 84 8.9 97 46.2 181 15.7
Total 940 100.0 210 100.0 1150 100.0

LDA, Low‐dose aspirin.

3.3. Preeclampsia in Patients Meeting LDA Criteria

Among women who met the criteria for LDA, the incidence of preeclampsia was statistically similar between those who were prescribed LDA and those who were not (p = 0.072). The number of risk factors was similar between the groups with and without aspirin recommendation. However, when evaluated according to risk value, the aspirin‐prescribed group had significantly higher risk values (p = 0.026) (Table 3).

TABLE 3.

Preeclampsia according to aspirin use in patients meeting LDA criteria (n = 210).

PE did not occur in the current pregnancy PE occured in the current pregnancy Total Risk value Number of risk factors
n % n % n % p Median IQR p Median IQR p
LDA‐ not prescribed in the current pregnancy 83 58.0 30 44.8 113 53.8 0.072 2 2‐3 0.026 3 3‐4 0.005
LDA‐ prescribed in the current pregnancy 60 42.0 37 55.2 97 46.2 2 2‐3 3 3‐5
Total 143 100.0 67 100.0 210 100.0

IQR, Inter quartile range; LDA, Low‐dose aspirin; PE, Preeclampsia.

Multivariable logistic regression analysis was performed and after adjustment for potential confounders, both chronic hypertension (OR 3.561, 95% CI 1.573–8.060, p = 0.002) and a BMI >35 kg/m2 (OR 2.275, 95% CI 1.081–4.789, p = 0.030) remained independently associated with an increased risk of preeclampsia among eligible women (n = 210) (Table 4).

TABLE 4.

Multivariable logistic regression analysis of factors associated with the development of preeclampsia among eligible women for LDA use (n = 210).

p OR 95% CI
Chronic hypertension 0.002 3.561 1.573‐8.060
Diabetes mellitus 0.105 0.449 0.171‐1.180
Primiparity 0.444 0.778 0.410‐1.479
LDA use in current pregnancy 0.176 0.649 0.347‐1.214
1st trimester BMI≥ 35 kg/m2 0.030 2.275 1.081‐4.789
Age ≥40 years 0.889 0.940 0.392‐2.251

BMI, Body mass index; LDA, Low‐dose aspirin.

3.4. LDA Use Among Women Who Developed Preeclampsia

A considerable proportion of women who subsequently developed preeclampsia had met criteria for LDA prophylaxis but had not received a prescription. This finding quantitatively supports the concept of a missed opportunity (p < 0.001) (Table 4).

Among women who developed preeclampsia, rates of LDA prescription were compared according to whether they met the criteria for LDA prophylaxis. LDA had not been prescribed to 44.8% of women who met the LDA criteria and to 79.5% of those who did not meet the criteria (p = 0.001) (Table 5).

TABLE 5.

Low‐dose aspirin use according to meeting LDA criteria among women who developed preeclampsia.

Not meeting criteria for LDA Meeting criteria for LDA Total p
n % n % n %
LDA‐ not prescribed in the current pregnancy 70 79.5 30 44.8 100 64.5 <0.001
LDA‐ prescribed in the current pregnancy 18 20.5 37 55.2 55 35.5
Total 88 100.0 67 100.0 155 100.0

LDA: Low‐dose aspirin, PE: Preeclampsia.

3.5. Preeclampsia among Women Who Had Not Used LDA

A total of 969 participants had not used LDA during their current pregnancy. Among these LDA non‐users, 11.7% (n = 113) met the criteria for LDA according to the Türkiye Guideline. Preeclampsia occurred approximately fourfold higher in women meeting LDA criteria than in those without LDA indication (26.5% and 8.2% respectively) (OR: 4.06 95% CI 2.50‐6.58, p < 0.001) (Table 6).

TABLE 6.

Preeclampsia among women who had not used LDA (n = 969).

Not meeting criteria for LDA Meeting criteria for LDA Total
n % n % N % OR (95% CI) p
PE did not occur in the current pregnancy 786 91.8 83 73.5 869 89.7 4.06 (2.5‐6.58) <0.001
PE occured in the current pregnancy 70 8.2 30 26.5 100 10.3
Total 856 100.0 113 100.0 969 100.0

LDA, Low‐dose aspirin; PE, Preeclampsia.

3.6. Initiation of LDA in Relation to Antenatal Follow‐Up Centre

Patients were evaluated for LDA prescription according to whether they were followed at a tertiary healthcare center before 16 weeks of gestation. The rate of LDA prescription was significantly higher among patients who were followed at a tertiary healthcare center at or before 16 weeks of gestation compared with those followed at other healthcare centers (p < 0.001). Similarly, in the subgroup of patients who met criteria for LDA the rate of aspirin prescription was also significantly higher among those followed at a tertiary healthcare center (p < 0.001) (Table 7). The number of risk factors was statistically similar between patients followed at tertiary healthcare centers and those not followed at tertiary centers, both among eligible cases (p = 0.753) and in the overall study population (p = 0.340).

TABLE 7.

Initiation of LDA in relation to early antenatal follow‐up at the tertiary center.

Non‐tertiary healthcare center follow‐up <16 weeks of gestation Tertiary healthcare center follow up <16 weeks of gestation Total
n % n % n % OR (95% CI) p
In the entire cohort (n = 1150)
LDA‐ not prescribed in the current pregnancy 517 88.8 452 79.6 969 84.3 2.04 (1.47‐2.84) <0.001
LDA‐ prescribed in the current pregnancy 65 11.2 116 20.4 181 15.7
Total 582 100.0 568 100.0 1150 100.0
median IQR (25‐75) median IQR (25‐75)
Number of risk factors * 1 0‐1 1 0‐1 0.340
n % n % n % OR (95% CI) p
In the cohort meeting criteria for LDA (n = 210)
LDA‐ not prescribed in the current pregnancy 67 69.8 46 40.4 113 53.8 3.42 (1.92‐6.07) <0.001
LDA‐ prescribed in the current pregnancy 29 30.2 68 59.6 97 46.2
Total 96 100.0 114 100.0 210 100.0
median IQR (25‐75) median IQR (25‐75)
Number of risk factors * 2 1‐2 2 1‐2 0.753
*

Mann‐Whitney U Test.

4. Discussion

4.1. Statement of Principal Findings

Despite well‐established guideline‐based indications, this study indicates a major missed prevention opportunity, as LDA was not administered to a substantial proportion of eligible women. Women who were followed at a tertiary healthcare center were more likely to receive a recommendation for LDA compared with those managed at other healthcare centers.

4.2. Strengths and Limitations

This study is the first to evaluate real‐world adherence to national guideline recommendations in Türkiye several years after their implementation. Strengths include the large sample size, use of objective prescription data, standardized risk assessment, and the ability of a tertiary referral center to capture routine clinical practice, thereby highlighting a clinically meaningful implementation gap relevant to healthcare quality.

The study is limited by its retrospective design, which depends on the accuracy and completeness of medical records. Provider knowledge and patient adherence to LDA were not evaluated. In addition, as the study was conducted in a tertiary care center, the findings may not be generalizable to the general population; however, they reflect real‐world clinical practice regarding guideline adherence. The risk value used in this study was based on a cumulative scoring approach rather than a validated risk prediction model. Therefore, it may not fully account for the differing clinical significance and relative contributions of individual major and minor risk factors. Although participant recruitment was limited to one designated weekday due to institutional regulations, obstetric care at our center is provided according to standardized protocols throughout the week. The selection bias cannot be excluded and the one‐day‐per‐week recruitment strategy may limit the representativeness of the sample.

4.3. Interpretation within the Context of the Wider Literature

Studies from low‐ and middle‐income countries (LMICs) consistently demonstrate substantial gaps in both knowledge and implementation of preventive strategies. A systematic review and meta‐analysis reported that the pooled level of knowledge regarding LDA prescription among obstetric care providers was as low as 16.38% in LMIC settings [14]. Similarly, in sub‐Saharan Africa, a very high proportion (98.9%) of eligible pregnant women did not receive aspirin prophylaxis despite clear indications, highlighting a major missed opportunity for prevention [15]. In line with these findings, studies from primary and referral healthcare settings have shown marked deficiencies in knowledge, with significantly lower awareness among providers in primary care compared to hospital‐based practitioners (7.1% vs 14.2%) [16]. Evidence from Ethiopia further supports this pattern, where only a minority of healthcare providers demonstrated good knowledge (23.8%) and practice (36.3%) regarding LDA prescription, and the absence of national guidelines was identified as a key barrier to implementation [17]. These findings imply that the main challenges to the effective implementation of LDA use in LMICs are inadequate dissemination of clinical guidelines and limited training opportunities.

Studies from high‐income or guideline‐established settings indicate that despite the existence of formal recommendations, adherence of healthcare providers to guidelines remains suboptimal. In one study, only 17.6% of women meeting high‐risk criteria for preeclampsia received LDA, and adherence remained low even when broader risk categories were considered (15.2%) [18]. The current study demonstrates a low rate of guideline‐based LDA prescription among women followed at different levels of healthcare centers but it does not assess healthcare providers’ knowledge levels, which represents an important limitation.

Similarly, in Israel, LDA prescription rates among eligible women were 44.1%, with higher uptake observed in women with major risk factors such as a history of preeclampsia or pregestational diabetes, while lower rates were reported among moderate‐risk groups [19]. A retrospective cohort study similarly demonstrated that only a subset of eligible patients receive LDA, and that prescription is more strongly associated with “high‐risk” classification [20].

In Türkiye, national guidelines defining risk‐based criteria for LDA initiation were updated in 2018. In the present study, conducted 5–7 years after this update, adherence to guideline‐based LDA prescription in the study population was 46.2%. This rate is comparable to other international reports but still indicates suboptimal implementation. These findings suggest that, despite the availability of resources and established guidelines, effective implementation remains closely linked to clinicians’ perception of patient risk.

The current study found that, among patients who met criteria for LDA in accordance with the guideline, obstetricians were more likely to initiate LDA in patients with a higher number of total minor and/or major risk factors. This finding may support the concern that patients with a lower number of risk factors, despite having an indication for LDA, might not receive preventive treatment. In this study, in the entire population preeclampsia occurred more frequently among women who were prescribed aspirin; however, this finding likely reflects confounding by indication rather than a lack of aspirin efficacy. These findings may reflect the underlying risk status of the women and should not be interpreted as evidence that the observed cases of preeclampsia could have been prevented by LDA. Moreover this study does not provide information on patients’ adherence to LDA treatment. Scientific evidence suggests that barriers to LDA implementation differ by healthcare context: in LMICs, limited guideline dissemination and knowledge gaps are dominant, whereas in higher‐income settings, incomplete adherence despite guideline availability is more closely related to clinical risk perception and selective prescribing behavior.

Appropriate selection of candidates for LDA prophylaxis is the first step toward successful prevention of preeclampsia. However, the effectiveness of LDA also depends on patient adherence after it has been prescribed. Adherence to LDA is lower than expected in routine clinical practice. Barriers and facilitators to LDA use during pregnancy have been systematically investigated. A recent systematic review evaluated adherence using the Capability, Opportunity, Motivation–Behavior (COM‐B) framework and examined the three stages of adherence: initiation, implementation, and discontinuation [21]. In a prospective observational study, aspirin nonadherence was quantitatively assessed in a high‐risk population. Women with adherence rates below 90% had significantly higher rates of preeclampsia and other adverse pregnancy outcomes [22]. This study did not assess patient adherence, persistence, or discontinuation of LDA after prescription. Therefore, the ″LDA prescribed″ group may not accurately reflect actual LDA use, and comparisons of preeclampsia outcomes between groups should be interpreted with caution.

4.4. Implications for Policy, Practice and Research

The Lalonde Report, published in 1974, highlighted four major interconnected factors that influence individual health: human biology, environment, lifestyle, and healthcare organization [23]. The first International Conference on Health Promotion in Ottawa, 1986, proposed five ideas. Reorienting health services is one of these strategies [24]. Studies reveal that, while there are variations, LDA prescribing rates for preeclampsia prevention are insufficient, regardless of the income level class of countries or the presence of national guidelines. It has been recommended to identify the barriers and facilitators that influence physicians' decisions and implementation of LDA prescribing [25]. In a systematic review of qualitative evidence, high and low intrinsic motivation among healthcare professionals were identified as the most important facilitators and barriers, respectively, to the implementation of clinical guidelines [26]. A holistic approach is particularly relevant for conditions like preeclampsia, a major contributor to maternal and neonatal morbidity, where effective prevention and management require coordinated efforts that integrate biological, environmental, lifestyle, and health system factors.

5. Conclusion

Republic of Türkiye Ministry of Health, ‘Prenatal Care and Management Guideline’ identified risk groups for the use of LDA to prevent preeclampsia in 2018. Despite strong guideline recommendations, adherence to LDA prescription for preeclampsia prevention remains suboptimal in the study population. Among women who developed preeclampsia, 44.8% of those who met the criteria for LDA prophylaxis had not been prescribed LDA. This finding supports a substantial missed opportunity for preeclampsia prophylaxis. Prescription rates were higher among pregnant women receiving care at tertiary healthcare centers than in other healthcare settings. The study was conducted in a major referral and educational center in Türkiye, where obstetric care is provided according to current national and international guidelines. Although the results cannot be directly extrapolated to the national level, they still provide important insight into real‐world prescribing practices in a high‐volume tertiary care setting and highlight that opportunities remain to improve adherence even in specialized centers. These findings highlight a substantial gap between evidence‐based guidelines and real‐world clinical practice, underscoring the need for targeted educational initiatives and system‐level interventions. Future national studies are warranted to investigate the barriers and facilitators that affect obstetricians' awareness and adherence to the guideline.

In this study, among women who developed preeclampsia, 44.8% of those who met the criteria for LDA prophylaxis had not been prescribed LDA. This finding supports a substantial missed opportunity for preeclampsia prophylaxis.

Author Contributions

Conceptualization, Nazan Usal Tarhan and Habibe Ayvacı Taşan; methodology, Nazan Usal Tarhan, Habibe Ayvacı Taşan; software, Habibe Ayvacı Taşan and Sevdenur Banu Yiğit, Mina Erbıyık; formal analysis, Nazan Usal Tarhan; investigation, Nazan Usal Tarhan and Nur Durcanoğlu; resources, Nazan Usal Tarhan, Nur Durcanoğlu; data curation, Nur Durcanoğlu, Sevdenur Banu Yiğit, Mina Erbıyık; writing – original draft preparation, Nazan Usal Tarhan, Habibe Ayvacı Taşan; writing – review and editing, Nazan Usal Tarhan, Habibe Ayvacı Taşan; supervision, Nazan Usal Tarhan, Habibe Ayvacı Taşan; project administration, Nazan Usal Tarhan, Habibe Ayvacı Taşan All authors approved the final version of the manuscript to be published.

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial or not – for‐profit sectors.

Ethics Approval Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Zeynep Kamil Women and Children's Diseases Training and Research Hospital Clinical Research Ethics Committee (Approval date/number: 20.09.2023/137).

Consent

All eligible participants were informed and invited to the study and an informed consent was obtained.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We would like to thank the healthcare professionals who collaborated throughout the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to ethical reasons (It can be shared after approval by the Ethics Committee).

References

  • 1. Say L., Chou D., Gemmill A., et al., “Global Causes of Maternal Death: a WHO Systematic Analysis,” Lancet Global health 2, no. 6 (2014): e323–e333, 10.1016/S2214-109X(14)70227-X. [DOI] [PubMed] [Google Scholar]
  • 2. Cresswell J. A., Alexander M., Chong M. Y. C., et al., “Global and Regional Causes of Maternal Deaths 2009–20: a WHO Systematic Analysis,” Lancet Global Health 13, no. 4 (2025): e626–e634, 10.1016/S2214-109X(24)00560-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Brosens I., Puttemans P., and Benagiano G., “Placental Bed Research: I. The Placental Bed: from Spiral Arteries Remodeling to the Great Obstetrical Syndromes,” American journal of obstetrics and gynecology 221, no. 5 (2019): 437–456, 10.1016/j.ajog.2019.05.044. [DOI] [PubMed] [Google Scholar]
  • 4. Chang K. J., Seow K. M., and Chen K. H., “Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life‐Threatening Condition,” International Journal of Environmental Research and Public Health 20, no. 4 (2023): 2994, 10.3390/ijerph20042994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. NICE Hypertension in Pregnancy (National Institute for Health and Care Excellence, 2013), https://www.nice.org.uk/guidance/qs35/chapter/quality‐statement‐2‐antenatal‐assessment‐of‐pre‐eclampsia‐risk/. [Google Scholar]
  • 6. ACOG , “Committee Opinion No. 743: Low‐Dose Aspirin Use during Pregnancy,” Obstetrics and Gynecology (2018) 132, no. 1: e44–e52, 10.1097/AOG.0000000000002708. [DOI] [PubMed] [Google Scholar]
  • 7. TRTHABER. Dünya Nüfus Günü Verileri Açıklandı. 2020. https://data.tuik.gov.tr/Bulten/Index?p=Dunya‐Nufus‐Gunu‐2020‐33707#:~:text=T%C3%BCrkiye'de%20.
  • 8. Keskinkılıç B., Engin‐Üstün Y., Sanisoğlu S., et al., “Maternal Mortality due to Hypertensive Disorders in Pregnancy, Childbirth, and the Puerperium between 2012 and 2015 in Turkey: a Nation‐Based Study,” Journal of the Turkish German Gynecological Association 18, no. 1 (2017): 20–25, 10.4274/jtgga.2016.0244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. T.C. Sağlık Bakanlığı Doğum Öncesi Bakım Yönetim Rehberi (T.C. Sağlık Bakanlığı, 2019), https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Rehberler/dogum_oncesi_bakim_08‐01‐2019_1.pdf. [Google Scholar]
  • 10. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines , Graham R, Mancher M, and Miller Wolman D, eds., Clinical Practice Guidelines We Can Trust (National Academies Press (US), 2011), https://www.ncbi.nlm.nih.gov/books/NBK209546/. [PubMed] [Google Scholar]
  • 11. LeFevre M. L., U.S. Preventive Services Task Force , “Low‐Dose Aspirin Use for the Prevention of Morbidity and Mortality from Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement,” Annals of Internal Medicine 161, no. 11 (2014): 819–826, 10.7326/M14-1884. [DOI] [PubMed] [Google Scholar]
  • 12. ESOMAR European Society for Opinion and Marketing Research , Hoffmeyer‐Zlotnik, J.H.P. and Wolf, C. , eds., “The ESOMAR Standard Demographic Classification,” in Advances in Cross‐National Comparison (Springer, 2003), 97–121, 10.1007/978-1-4419-9186-7_6. [DOI] [Google Scholar]
  • 13.“Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222,” Obstetrics and gynecology (2020) 135, no. 6: e237–e260, 10.1097/AOG.0000000000003891. [DOI] [PubMed] [Google Scholar]
  • 14. Lake E. S., Ayele M., Tilahun B. D., Erega B. B., Belay A. S., and Yilak G., “Obstetric Care Provider's Knowledge about the Use of Low Dose Aspirin for Preeclampsia Prevention in Low and Middle Income Countries: a Systematic Review and Meta‐Analysis,” BMC Pregnancy and Childbirth 24, no. 1 (2024): 611, 10.1186/s12884-024-06803-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Sium A. F., Gudu W., Tolu L. B., Birara M., and Bekele D., “Missed Opportunity for Aspirin Prophylaxis for Preeclampsia Prevention: a Cross‐Sectional Study from Sub‐Saharan Africa,” AJOG Global Reports 4, no. 1 (2023): 100295, 10.1016/j.xagr.2023.100295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Nkamba D. M., Vangu R., Elongi M., et al., “Health Facility Readiness and Provider Knowledge as Correlates of Adequate Diagnosis and Management of Pre‐Eclampsia in Kinshasa, Democratic Republic of Congo,” BMC Health Services Research 20, no. 1 (2020): 926, 10.1186/s12913-020-05795-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Bekele D., Gudu W., Tolu L. B., Birara M., and Sium A. F., “Preeclampsia Prevention: a Survey Study on Knowledge and Practice among Prenatal Care Providers in Ethiopia,” AJOG Global Reports 4, no. 1 (2023): 100300, 10.1016/j.xagr.2023.100300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Ayyash M., Goyert G., Pitts D., et al., “Provider Adherence to Aspirin Prophylaxis Prescription Guidelines for Preeclampsia,” Pregnancy Hypertension 34 (2023): 1–4, 10.1016/j.preghy.2023.09.002. [DOI] [PubMed] [Google Scholar]
  • 19. Ganem N., Frank Wolf M., Kayal R. S., et al., “Gaps in Low‐Dose Aspirin Use for Preeclampsia Prevention: Insights and Clinical Implications,” International Journal of Women's Health 17 (2025): 2909–2917, 10.2147/IJWH.S536497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Phelps A. J. D. and Holmgren C., “Relationship between Risk Factor Profile and Prescription of Low‐Dose Aspirin for Preeclampsia Prevention,” Archives of Gynecology and Obstetrics 308, no. 4 (2023): 1279–1286, 10.1007/s00404-022-06773-0. [DOI] [PubMed] [Google Scholar]
  • 21. Vinogradov R., Holden E., Patel M., et al., “Barriers and Facilitators of Adherence to Low‐Dose Aspirin during Pregnancy: a Co‐Produced Systematic Review and COM‐B Framework Synthesis of Qualitative Evidence,” PloS One 19, no. 5 (2024): e0302720, 10.1371/journal.pone.0302720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Shanmugalingam R., Wang X., Motum P., et al., “Clinical Influence of Nonadherence with Prophylactic Aspirin in Preventing Preeclampsia in High‐Risk Pregnancies: a Multicenter, Prospective, Observational Cohort Study,” Hypertension 75, no. 4 (2020): 1125–1132, 10.1161/HYPERTENSIONAHA.119.14107. [DOI] [PubMed] [Google Scholar]
  • 23. Lalonde M.. A New Perspective on the Health of Canadians. 1974. https://www.phac‐aspc.gc.ca/ph‐sp/pdf/perspect‐eng.pdf.
  • 24. WHO World Health Organization Health Determinants, Promotion and Prevention (WHO, 1986), https://www.who.int/teams/health‐promotion/enhanced‐wellbeing/first‐global‐conference. [Google Scholar]
  • 25. Davies A., Chapman S., Mullin S., et al., “Qualitative Study Exploring the Barriers and Facilitators to Low‐Dose Aspirin Adherence in Pregnant Women with Placental Dysfunction Risk in the UK,” BMJ Open 15, no. 3 (2025): e093888, 10.1136/bmjopen-2024-093888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Stokes T., Shaw E. J., Camosso‐Stefinovic J., Imamura M., Kanguru L., and Hussein J., “Barriers and Enablers to Guideline Implementation Strategies to Improve Obstetric Care Practice in Low‐ and Middle‐Income Countries: a Systematic Review of Qualitative Evidence,” Implementation science: IS 11, no. 1 (2016): 144, 10.1186/s13012-016-0508-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to ethical reasons (It can be shared after approval by the Ethics Committee).


Articles from The Journal of Clinical Hypertension are provided here courtesy of Wiley

RESOURCES